„BioNTech plans to shrink its workforce and manufacturing network, as the German biotech company seeks to cut costs and downsize its footprint after demand for Covid-19 vaccines waned.
The move means the company is set to hand full responsibility over the supply of its Covid shot to partner Pfizer, BioNTech Chief Financial Officer Ramon Zapata said, after both companies teamed up to bring the vaccine to market during the pandemic.
BioNTech is looking to pivot to cancer therapies, and earlier this year it said its co-founders would leave the company by the end of the year to form a new startup focused on messenger RNA technology.
The company said it would exit some manufacturing plants in Germany and Singapore, as well as sites it acquired as part of its CureVac takeover.
As many as 1,860 roles will be affected by the plan, it added. This would represent roughly 22% of the company's workforce.
BioNTech has a global head count of about 8,400 people, according to a company spokeswoman.
A plant in Marburg, Germany, which BioNTech previously called one of the largest mRNA vaccine manufacturing sites globally, is among the facilities the company is exiting. The company said it was exploring partial or total sales for each of the sites.
The company said the plan sought to consolidate its manufacturing network where it expected excess capacity and align its footprint with supply needs, acquisitions, the capacity of its partners and the completion of contracts.
BioNTech projected the move would lead to potentially 500 million euros, equivalent to $584.6 million, in recurring annual savings in 2029, which it intends to deploy to move its oncology pipeline toward commercialization.
The company is testing several cancer-drug candidates in late-stage clinical trials and has projected research-and-development expenses to outstrip revenue this year, an outlook it reiterated.
For the first quarter, BioNTech's revenue declined to 118.1 million euros from 182.8 million euros for the same period last year. Zapata said the result reflected seasonal demand for Covid vaccines and was in line with the company's expectations.
Its net loss widened to 531.9 million euros from a loss of 415.8 million euros.“ [1]
Survival results from BioNTech mRNA cancer vaccines and related mRNA-enhanced immunotherapy are considered remarkably promising, particularly in treating deadly or advanced cancers. Key findings indicate dramatically enhanced immune responses, with some trials showing patients surviving years longer than expected.
Remarkable Findings in Cancer Vaccine Trials
• Pancreatic Cancer: A Phase 1 trial on individualized mRNA vaccines (autogene cevumeran) developed by BioNTech and Genentech showed that nearly 90% of patients whose immune systems responded to the vaccine were still alive up to six years after treatment. Given that pancreatic cancer has a very low five-year survival rate (approx. 13%), this long-term survival is exceptional.
• Melanoma & NSCLC: Research published in late 2025 indicated that mRNA-based COVID-19 vaccines could "turbocharge" checkpoint inhibitor immunotherapy, roughly doubling median survival rates for advanced lung cancer and metastatic melanoma when administered together.
• Sustained Response: The vaccines have demonstrated the ability to create a durable, long-term immune memory, preventing cancer recurrence, which is a major milestone in personalized cancer care.
Key Takeaways
• Mechanism: These mRNA vaccines act as a "siren call" to the immune system, transforming unresponsive cancers into responsive ones by triggering a massive immune response.
• Impact: The combined approach of mRNA vaccines and checkpoint inhibitors has produced 3-year survival improvements of up to 40%–60% in certain advanced cases.
• Context: While results are groundbreaking, they come from early-phase or observational studies, and large-scale, randomized trials are ongoing to confirm these findings.
1. BioNTech to Shed Jobs and Plants As Sales of Covid Vaccines Dwindle. Calatayud, Adria. Wall Street Journal, Eastern edition; New York, N.Y.. 06 May 2026: B5.
Komentarų nėra:
Rašyti komentarą